FDA Appoints Richard Pazdur as New Director of CDER

Background on Richard Pazdur

On Tuesday, the Food and Drug Administration (FDA) announced the appointment of Richard Pazdur, a seasoned veteran within the agency’s oncology division, as the new director of the Center for Drug Evaluation and Research (CDER). Pazdur has been with the FDA since 1999 and was the founding director of the Oncology Center of Excellence, established in 2017. The agency recognized him as a “renowned regulatory innovator” who has implemented numerous initiatives aimed at expediting the approval process for new cancer treatments.

Transition from George Tidmarsh

Pazdur’s appointment comes after the brief and contentious tenure of George Tidmarsh, who took over the CDER directorship in July. Tidmarsh faced criticism for questioning the safety of an approved drug from Aurinia Pharmaceuticals in a social media post, leading to his resignation this month amid an investigation into his conduct.

The Role of CDER and Its Significance

Importance of the CDER Directorship

The director of CDER holds significant influence within the FDA, second only to Commissioner Marty Makary. This center is responsible for reviewing nearly all new drug applications, excluding vaccines and gene and cell therapies. It regulates a wide range of products from over-the-counter medications to sunscreen.

Pazdur’s Leadership Style and Industry Impact

As the previous head of the oncology unit, Pazdur demonstrated thoughtful leadership by accelerating drug approvals while also advocating for the withdrawal of medications that did not meet expectations. RBC Capital Markets analyst Brian Abrahams noted that Pazdur’s leadership is indicative of Makary’s preference for “stable leadership.” Abrahams described Pazdur as “arguably the most qualified candidate in the entire healthcare ecosystem for this role,” predicting that his leadership will likely mitigate controversies or negative headlines that have recently unsettled healthcare investors.

Challenges Facing the FDA

Recent Turmoil Within the Agency

The FDA has experienced significant turmoil since the onset of the second Trump administration, with key officials resigning amidst mass layoffs and reports of a toxic work environment, particularly within the biologics division. Vinay Prasad, a critic of the FDA, was appointed to lead the Center for Biologics Evaluation and Research in May, resigned in July, and returned to the position in August.

Unpredictability in Regulatory Reviews

Industry observers have noted an increasing unpredictability in the FDA’s regulatory reviews, with the agency reportedly shifting its stance on applications and catching companies off guard. A recent example involved UniQure, which announced that the FDA had unexpectedly changed its outlook on an experimental gene therapy for Huntington’s disease. This disorganized review process has drawn criticism from the Wall Street Journal and left company executives feeling anxious.

Outlook for Pazdur’s Leadership

Abrahams expressed optimism that Pazdur’s leadership would alleviate ongoing regulatory uncertainties. The industry is likely to welcome his appointment, as he is expected to provide a steady guidance during a time characterized by an increase in review delays.